What is Pheast?
Founded in 2020 and headquartered in Palo Alto, California, Pheast Therapeutics operates at the intersection of immunology and oncology. The company is dedicated to the development of novel checkpoint therapies designed to harness the innate immune system to combat malignant tumors. By focusing on the mechanisms that allow cancer cells to evade immune detection, Pheast aims to create a new generation of therapeutic interventions that offer superior efficacy compared to existing standards of care. Its market position is defined by a rigorous scientific approach, targeting high-unmet-need indications within the oncology space.
How much funding has Pheast raised?
Pheast has raised a total of $76M across 1 funding round:
Series A
$76M
Series A (2022): $76M with participation from Catalio Capital Management, Risk and Return, Alexandria Venture Investments, and ARCH Venture Partners
Key Investors in Pheast
Catalio Capital Management
A New York-based investment firm specializing in innovative healthcare investing across private, public, and credit markets, with a focus on breakthrough biomedical technology.
ARCH Venture Partners
A leading early-stage venture capital firm that creates and invests in life sciences and advanced technology companies, often co-founding startups to commercialize academic and corporate research.
Risk and Return
A venture capital firm focused on investing in companies that enhance national resilience and address various risks through innovative solutions.
What's next for Pheast?
With the recent capital injection, Pheast Therapeutics is expected to prioritize the expansion of its clinical trial infrastructure and the acceleration of its lead therapeutic programs. The strategic focus will likely shift toward optimizing its checkpoint blockade technology and strengthening its intellectual property portfolio. Furthermore, the company is poised to leverage its strong investor syndicate to facilitate potential partnerships and talent acquisition, ensuring it remains at the forefront of the competitive immunotherapy market. As the firm moves forward, the primary objective will be to demonstrate clinical proof-of-concept, a critical step in validating its long-term commercial viability and therapeutic impact.
See full Pheast company page
